{"id":2767,"date":"2020-08-01T12:04:00","date_gmt":"2020-08-01T10:04:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2020\/die-empfehlungen-der-european-society-of-cardiology-zur-praevention-kardiovaskulaerer-erkrankungen-anspruch-und-wirklichkeit"},"modified":"2020-08-01T12:04:00","modified_gmt":"2020-08-01T10:04:00","slug":"die-empfehlungen-der-european-society-of-cardiology-zur-praevention-kardiovaskulaerer-erkrankungen-anspruch-und-wirklichkeit","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2020\/die-empfehlungen-der-european-society-of-cardiology-zur-praevention-kardiovaskulaerer-erkrankungen-anspruch-und-wirklichkeit","title":{"rendered":"Die Empfehlungen der European Society of Cardiology zur Pr\u00e4vention kardiovaskul\u00e4rer Erkrankungen: Anspruch und Wirklichkeit"},"content":{"rendered":"<p>In der Swiss Medical Weekly erschien im Mai eine bemerkenswerte Analyse des haus\u00e4rztlichen Managements bei kardiovaskul\u00e4ren Risikopatienten in der Schweiz (1). Darin wurde die Umsetzung der von der europ\u00e4ischen Gesellschaft f\u00fcr Kardiologie (ESC) in ihren Leitlinien von 2016 vorgegebenen Therapieziele bez\u00fcglich des LDL-Cholesterins (LDL-C) im Jahre 2018 untersucht. Damals galten als Ziele (2): bei geringem\/moderatem [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In der Swiss Medical Weekly erschien im Mai eine bemerkenswerte Analyse des haus\u00e4rztlichen Managements bei kardiovaskul\u00e4ren Risikopatienten in der Schweiz (1). Darin wurde die Umsetzung der von der europ\u00e4ischen Gesellschaft f\u00fcr Kardiologie (ESC) in ihren Leitlinien von 2016 vorgegebenen Therapieziele bez\u00fcglich des LDL-Cholesterins (LDL-C) im Jahre 2018 untersucht. Damals galten als Ziele (2): bei geringem\/moderatem [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[684,495,60,1272,1274,451,449,71,455,453,498,3066,456,65,1526,1522,56,443],"class_list":["post-2767","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-akutes-koronarsyndrom","tag-angina-pectoris","tag-apoplektischer-insult","tag-arteriosklerose","tag-cholesterin","tag-cholesterinsynthese-hemmer","tag-cse-hemmer","tag-herzinfarkt","tag-hmg-coa-reduktase-hemmer","tag-hypercholesterinaemie","tag-koronare-herzkrankheit","tag-ldl-cholesterin","tag-lipidsenker","tag-myokardinfarkt","tag-pcsk9-antikoerper","tag-pcsk9-hemmer","tag-schlaganfall","tag-statine"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2767","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2767"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2767\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2767"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2767"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2767"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}